Antisense therapy in neurology

Journal of Personalized Medicine

Volumn 3, Issue 3, 2013, Pages 144-176

  Lee, Joshua ^a   Yokota, Toshifumi ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b The Friends of Garret Cumming Research   (Canada)

Author keywords

Amyotrophic lateral sclerosis (ALS); Antisense therapy; Distal myopathy with anterior tibial onset (DMAT); Duchenne muscular dystrophy (DMD); Fukuyama congenital muscular dystrophy (FCMD); Huntington's disease (HD); Limb girdle muscular dystrophy 2B (LGMD2B); Miyoshi myopathy (MM); Myotonic dystrophy (DM); Spinal muscular atrophy (SMA)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COPPER ZINC SUPEROXIDE DISMUTASE; DRISAPERSEN; DYSFERLIN; ETEPLIRSEN; FOMIVIRSEN; ISIS 333611; ISIS SMNRX; LOCKED NUCLEIC ACID; MIPOMERSEN; MORPHOLINO OLIGONUCLEOTIDE; MYOTONIC DYSTROPHY PROTEIN KINASE; NCNP 01; NS 065; PRO135; PRO289; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; CHEMISTRY; CYTOMEGALOVIRUS RETINITIS; DISTAL MYOPATHY; DRUG DELIVERY SYSTEM; DUCHENNE MUSCULAR DYSTROPHY; DYSFERLINOPATHY; EXON SKIPPING; FAMILIAL HYPERCHOLESTEROLEMIA; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; LIMB GIRDLE MUSCULAR DYSTROPHY; MIYOSHI MYOPATHY; MYOTONIC DYSTROPHY; NEUROLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RNA SPLICING; SPINAL MUSCULAR ATROPHY;

EID: 84893552611     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm3030144     Document Type: Review

References (253)

1. Kuzmiak, H.A.; Maquat, L.E. Applying nonsense-mediated mRNA decay research to the clinic: Progress and challenges. Trends Mol. Med. 2006, 12, 306-316.
2. Bennett, C.F.; Condon, T.P.; Grimm, S.; Chan, H.; Chiang, M.Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. 1994, 152, 3530-3540.
3. Jiang, K. Biotechcomestoitsantisensesafterhard-won drug approval. Nat. Med. 2013, 19, doi:10.1038/nm0313-252.
4. Bendifallah, N.; Rasmussen, F.W.; Zachar, V.; Ebbesen, P.; Nielsen, P.E.; Koppelhus, U. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug. Chem. 2006, 17, 750-758.
5. Miller, P.S.; Braiterman, L.T.; Ts'o, P.O. Effects of a trinucleotide ethyl phosphotriester, Gmp(Et)Gmp(Et)U, on mammalian cells in culture. Biochemistry 1977, 16, 1988-1996.
6. Shiraishi, T.; Nielsen, P.E. Improved cellular uptake of antisense peptide nucleic acids by conjugation to a cell-penetrating peptide and a lipid domain. Methods Mol. Biol. 2011, 751, 209-221.
7. Torchilin, V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8, 343-375.
8. Kazantsev, A.G.; Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7, 854-868.
9. Muntoni, F.; Wood, M.J. Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov. 2011, 10, 621-637.
10. Iwasaki, A.; Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5, 987-995.
11. Hoffman, E.P.; Bronson, A.; Levin, A.A.; Takeda, S.; Yokota, T.; Baudy, A.R.; Connor, E.M. Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am. J. Pathol. 2011, 179, 12-22.
12. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6, 686-695.
13. Broaddus, W.C.; Prabhu, S.S.; Gillies, G.T.; Neal, J.; Conrad, W.S.; Chen, Z.J.; Fillmore, H.; Young, H.F. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. Neurosurg. Focus 1997, 3, e6.
14. Wahlestedt, C.; Salmi, P.; Good, L.; Kela, J.; Johnsson, T.; Hokfelt, T.; Broberger, C.; Porreca, F.; Lai, J.; Ren, K.; et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA 2000, 97, 5633-5638.
15. Pardridge, W.M. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 1997, 17, 713-731.
16. Smith, R.A.; Miller, T.M.; Yamanaka, K.; Monia, B.P.; Condon, T.P.; Hung, G.; Lobsiger, C.S.; Ward, C.M.; McAlonis-Downes, M.; Wei, H.; et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 2006, 116, 2290-2296.
17. Lu, Q.L.; Rabinowitz, A.; Chen, Y.C.; Yokota, T.; Yin, H.; Alter, J.; Jadoon, A.; Bou-Gharios, G.; Partridge, T. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. USA 2005, 102, 198-203.
18. Heemskerk, H.A.; de Winter, C.L.; de Kimpe, S.J.; van Kuik-Romeijn, P.; Heuvelmans, N.; Platenburg, G.J.; van Ommen, G.J.; van Deutekom, J.C.; Aartsma-Rus, A. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 2009, 11, 257-266.
19. Yokota, T.; Lu, Q.L.; Partridge, T.; Kobayashi, M.; Nakamura, A.; Takeda, S.; Hoffman, E. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 2009, 65, 667-676.
20. Goemans, N.M.; Tulinius, M.; van den Akker, J.T.; Burm, B.E.; Ekhart, P.F.; Heuvelmans, N.; Holling, T.; Janson, A.A.; Platenburg, G.J.; Sipkens, J.A.; et al. Systemic administration of PRO051inDuchenne'smusculardystrophy. N. Engl. J. Med. 2011, 364, 1513-1522.
21. van Deutekom, J.C.; Janson, A.A.; Ginjaar, I.B.; Frankhuizen, W.S.; Aartsma-Rus, A.; Bremmer-Bout, M.; den Dunnen, J.T.; Koop, K.; van der Kooi, A.J.; Goemans, N.M.; et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 2007, 357, 2677-2686.
22. Moulton, J.D.; Jiang, S. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 2009, 14, 1304-1323.
23. Sazani, P.; Ness, K.P.; Weller, D.L.; Poage, D.W.; Palyada, K.; Shrewsbury, S.B. Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Int. J. Toxicol. 2011, 30, 313-321.
24. Altmann, K.H.; Fabbro, D.; Dean, N.M.; Geiger, T.; Monia, B.P.; Muller, M.; Nicklin, P. Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem. Soc. Trans. 1996, 24, 630-637.
25. Monia, B.P.; Lesnik, E.A.; Gonzalez, C.; Lima, W.F.; McGee, D.; Guinosso, C.J.; Kawasaki, A.M.; Cook, P.D.; Freier, S.M. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 1993, 268, 14514-14522.
26. Prakash, T.P.; Bhat, B. 2'-Modified oligonucleotides for antisense therapeutics. Curr. Top. Med. Chem. 2007, 7, 641-649.
27. Wheeler, T.M.; Leger, A.J.; Pandey, S.K.; MacLeod, A.R.; Nakamori, M.; Cheng, S.H.; Wentworth, B.M.; Bennett, C.F.; Thornton, C.A. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012, 488, 111-115.
28. Aoki, Y.; Yokota, T.; Nagata, T.; Nakamura, A.; Tanihata, J.; Saito, T.; Duguez, S.M.; Nagaraju, K.; Hoffman, E.P.; Partridge, T.; et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. USA 2012, 109, 13763-13768.
29. Taniguchi-Ikeda, M.; Kobayashi, K.; Kanagawa, M.; Yu, C.C.; Mori, K.; Oda, T.; Kuga, A.; Kurahashi, H.; Akman, H.O.; DiMauro, S.; et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 2011, 478, 127-131.
30. Yokota, T.; Nakamura, A.; Nagata, T.; Saito, T.; Kobayashi, M.; Aoki, Y.; Echigoya, Y.; Partridge, T.; Hoffman, E.P.; Takeda, S. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther. 2012, 22, 306-315.
31. Yin, H.; Moulton, H.M.; Seow, Y.; Boyd, C.; Boutilier, J.; Iverson, P.; Wood, M.J. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 2008, 17, 3909-3918.
32. Yin, H.; Saleh, A.F.; Betts, C.; Camelliti, P.; Seow, Y.; Ashraf, S.; Arzumanov, A.; Hammond, S.; Merritt, T.; Gait, M.J.; et al. Pip5 transduction peptides direct high efficiency oligonucleotidemediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 2011, 19, 1295-1303.
33. Yin, H.; Moulton, H.M.; Betts, C.; Seow, Y.; Boutilier, J.; Iverson, P.L.; Wood, M.J. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 2009, 18, 4405-4414.
34. Yin, H.; Moulton, H.; Betts, C.; Wood, M. CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy. Methods Mol. Biol. 2011, 683, 321-338.
35. Yin, H.; Lu, Q.; Wood, M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 2008, 16, 38-45.
36. Yin, H.; Betts, C.; Saleh, A.F.; Ivanova, G.D.; Lee, H.; Seow, Y.; Kim, D.; Gait, M.J.; Wood, M.J. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol. Ther. 2010, 18, 819-827.
37. Wu, B.; Moulton, H.M.; Iversen, P.L.; Jiang, J.; Li, J.; Li, J.; Spurney, C.F.; Sali, A.; Guerron, A.D.; Nagaraju, K.; et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl. Acad. Sci. USA 2008, 105, 14814-14819.
38. Egholm, M.; Buchardt, O.; Christensen, L.; Behrens, C.; Freier, S.M.; Driver, D.A.; Berg, R.H.; Kim, S.K.; Norden, B.; Nielsen, P.E. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993, 365, 566-568.
39. Karkare, S.; Bhatnagar, D. Promising nucleic acid analogs and mimics: Characteristic features and applications of PNA, LNA, and morpholino. Appl. Microbiol. Biotechnol. 2006, 71, 575-586.
40. Ivanova, G.D.; Arzumanov, A.; Abes, R.; Yin, H.; Wood, M.J.; Lebleu, B.; Gait, M.J. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res.2008, 36, 6418-6428.
41. Pfundheller, H.M.; Lomholt, C. Locked nucleic acids: Synthesis and characterization of LNA-T diol. Curr. Protoc. Nucleic Acid Chem. 2002, doi: 10.1002/0471142700.nc0412s08
42. Singh, S.K.; Kumar, R.; Wengel, J. Synthesis of Novel Bicyclo [2.2.1] Ribonucleosides: 2'-Amino- and 2'-Thio-LNA Monomeric Nucleosides. J. Org. Chem. 1998, 63, 6078-6079.
43. McTigue, P.M.; Peterson, R.J.; Kahn, J.D. Sequence-dependent thermodynamic parameters for locked nucleic acid (LNA)-DNA duplex formation. Biochemistry 2004, 43, 5388-5405.
44. Kumar, R.; Singh, S.K.; Koshkin, A.A.; Rajwanshi, V.K.; Meldgaard, M.; Wengel, J. The first analogues of LNA (locked nucleic acids): Phosphorothioate-LNA and 2'-thio-LNA. Bioorg. Med. Chem. Lett.1998, 8, 2219-2222.
45. Tolstrup, N.; Nielsen, P.S.; Kolberg, J.G.; Frankel, A.M.; Vissing, H.; Kauppinen, S. Oligo Design: Optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. Nucleic Acids Res.2003, 31, 3758-3762.
46. Johnson, M.P.; Haupt, L.M.; Griffiths, L.R. Locked nucleic acid (LNA) single nucleotide polymorphism (SNP) genotype analysis and validation using real-time PCR. Nucleic Acids Res. 2004, 32, e55.
47. Latorra, D.; Campbell, K.; Wolter, A.; Hurley, J.M. Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers. Hum. Mutat. 2003, 22, 79-85.
48. Simeonov, A.; Nikiforov, T.T. Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Acids Res.2002, 30, e91.
49. Petersen, M.; Wengel, J. LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol. 2003, 21, 74-81.
50. Sood, A.; Spielvogel, B.F.; Shaw, B.R.; Carlton, L.D.; Burnham, B.S.; Hall, E.S.; Hall, I.H. The synthesis and antineoplastic activity of 2'-deoxy-nucleoside-cyanoboranes in murine and human culture cells. Anticancer Res. 1992, 12, 335-343.
51. Rait, V.K.; Shaw, B.R. Boranophosphates support the RNase H cleavage of polyribonucleotides. Antisense Nucleic Acid Drug Dev. 1999, 9, 53-60.
52. Rait, V.; Sergueev, D.; Summers, J.; He, K.; Huang, F.; Krzyzanowska, B.; Shaw, B.R. Boranophosphate nucleic acids-A versatile DNA backbone. Nucleos. Nucleot. 1999, 18, 1379-1380.
53. Li, P.; Shaw, B.R. Synthesis of prodrug candidates: Conjugates of amino acid with nucleoside boranophosphate. Org. Lett. 2002, 4, 2009-2012.
54. Shaw, B.R.; Dobrikov, M.; Wang, X.; Wan, J.; He, K.; Lin, J.L.; Li, P.; Rait, V.; Sergueeva, Z.A.; Sergueev, D. Reading, writing, and modulating genetic information with boranophosphate mimics of nucleotides, DNA, and RNA. Ann. N. Y. Acad. Sci. 2003, 1002, 12-29.
55. Shaw, B.R.; Sergueev, D.; He, K.; Porter, K.; Summers, J.; Sergueeva, Z.; Rait, V. Boranophosphate backbone: A mimic of phosphodiesters, phosphorothioates, and methyl phosphonates. Meth. Enzymol. 2000, 313, 226-257.
56. Opalinska, J.B.; Kalota, A.; Gifford, L.K.; Lu, P.; Jen, K.Y.; Pradeepkumar, P.I.; Barman, J.; Kim, T.K.; Swider, C.R.; Chattopadhyaya, J.; et al. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Res.2004, 32, 5791-5799.
57. Opalinska, J.B.; Gewirtz, A.M. Rationally targeted, conformationally constrained, oxetane-modified oligonucleotides demonstrate efficient gene-silencing activity in a cellular system. Ann. N. Y. Acad. Sci. 2005, 1058, 39-51.
58. Carroll, J.B.; Warby, S.C.; Southwell, A.L.; Doty, C.N.; Greenlee, S.; Skotte, N.; Hung, G.; Bennett, C.F.; Freier, S.M.; Hayden, M.R. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther. 2011, 19, 2178-2185.
59. Hua, X.; Yu, L.; Huang, X.; Liao, Z.; Xian, Q. Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn. Pathol. 2011, 6, e111.
60. Miller, T.M.; Pestronk, A.; David, W.; Rothstein, J.; Simpson, E.; Appel, S.H.; Andres, P.L.; Mahoney, K.; Allred, P.; Alexander, K.; et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013, 12, 435-442.
61. Sah, D.W.; Aronin, N. Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest. 2011, 121, 500-507.
62. Heemskerk, H.; de Winter, C.; van Kuik, P.; Heuvelmans, N.; Sabatelli, P.; Rimessi, P.; Braghetta, P.; van Ommen, G.J.; de Kimpe, S.; Ferlini, A.; et al. Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 2010, 18, 1210-1217.
63. Kim, Y.; Tewari, M.; Pajeroski, D.J.; Sen, S.; Jason, W.; Sirsi, S.; Lutz, G.; Discher, D.E. Efficient nuclear delivery and nuclear body localization of antisense oligo-nucleotides using degradable polymersomes. In Proceedings of the Engineering in Medicine and Biology Society, 2006. EMBS'06. 28th Annual International Conference of the IEEE, New York, NY, USA, 30 August-3 September 2006; pp. 4350-4353.
64. Hoffman, E.P. Skipping toward personalized molecular medicine. N. Engl. J. Med. 2007, 357, 2719-2722.
65. Yokota, T.; Pistilli, E.; Duddy, W.; Nagaraju, K. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin. Biol. Ther. 2007, 7, 831-842.
66. Yokota, T.; Duddy, W.; Echigoya, Y.; Kolski, H. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: Too many mutations, too few patients? Expert Opin. Biol. Ther. 2012, 12, 1141-1152.
67. Malerba, A.; Boldrin, L.; Dickson, G. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: Implications for cardiac muscle integrity. Nucleic Acid Ther. 2011, 21, 293-298.
68. Wheeler, T.M. Myotonic dystrophy: Therapeutic strategies for the future. Neurotherapeutics 2008, 5, 592-600.
69. Hua, Y.; Vickers, T.A.; Baker, B.F.; Bennett, C.F.; Krainer, A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007, 5, e73.
70. Porensky, P.N.; Mitrpant, C.; McGovern, V.L.; Bevan, A.K.; Foust, K.D.; Kaspar, B.K.; Wilton, S.D.; Burghes, A.H. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 2012, 21, 1625-1638.
71. Duchenne, G.B. The pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. Br. Med. J. 1867, 2, 541-542.
72. Hoffman, E.P.; Brown, R.H., Jr.; Kunkel, L.M. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51, 919-928.
73. Koenig, M.; Hoffman, E.P.; Bertelson, C.J.; Monaco, A.P.; Feener, C.; Kunkel, L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987, 50, 509-517.
74. Lu, Q.L.; Yokota, T.; Takeda, S.; Garcia, L.; Muntoni, F.; Partridge, T. The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol. Ther. 2011, 19, 9-15.
75. Aartsma-Rus, A. Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy. RNA Biol. 2010, 7, 453-461.
76. Yokota, T.; Duddy, W.; Partridge, T. Optimizing exon skipping therapies for DMD. Acta Myol. 2007, 26, 179-184.
77. Yokota, T.; Lu, Q.L.; Morgan, J.E.; Davies, K.E.; Fisher, R.; Takeda, S.; Partridge, T.A. Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J. Cell Sci. 2006, 119, 2679-2687.
78. Hoffman, E.P.; Morgan, J.E.; Watkins, S.C.; Partridge, T.A. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J. Neurol. Sci. 1990, 99, 9-25.
79. Klein, C.J.; Coovert, D.D.; Bulman, D.E.; Ray, P.N.; Mendell, J.R.; Burghes, A.H. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): Evidence supporting a framerestoring mechanism in rare dystrophin-positive fibers. Am. J. Hum. Genet. 1992, 50, 950-959.
80. Lu, Q.L.; Morris, G.E.; Wilton, S.D.; Ly, T.; Artem'yeva, O.V.; Strong, P.; Partridge, T.A. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J. Cell Biol. 2000, 148, 985-996.
81. Echigoya, Y.; Lee, J.; Rodrigues, M.; Nagata, T.; Tanihata, J.; Nozohourmehrabad, A.; Panesar, D.; Miskew, B.; Aoki, Y.; Yokota, T. Mutation types and aging differently affect revertant fiber expansion in dystrophic Mdx and Mdx52 mice. PLoS One 2013, in press.
82. Aoki, Y.; Nakamura, A.; Yokota, T.; Saito, T.; Okazawa, H.; Nagata, T.; Takeda, S. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol. Ther. 2010, 18, 1995-2005.
83. Saito, T.; Nakamura, A.; Aoki, Y.; Yokota, T.; Okada, T.; Osawa, M.; Takeda, S. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 2010, 5, e12239.
84. Aartsma-Rus, A.; de Winter, C.L.; Janson, A.A.; Kaman, W.E.; van Ommen, G.J.; den Dunnen, J.T.; van Deutekom, J.C. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: Indication for steric hindrance of SR protein binding sites. Oligonucleotides 2005, 15, 284-297.
85. Aartsma-Rus, A.; Janson, A.A.; Kaman, W.E.; Bremmer-Bout, M.; den Dunnen, J.T.; Baas, F.; van Ommen, G.J.; van Deutekom, J.C. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 2003, 12, 907-914.
86. Bertoni, C.; Lau, C.; Rando, T.A. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping. Hum. Mol. Genet. 2003, 12, 1087-1099.
87. Bremmer-Bout, M.; Aartsma-Rus, A.; de Meijer, E.J.; Kaman, W.E.; Janson, A.A.; Vossen, R.H.; van Ommen, G.J.; den Dunnen, J.T.; van Deutekom, J.C. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol. Ther. 2004, 10, 232-240.
88. Fletcher, S.; Honeyman, K.; Fall, A.M.; Harding, P.L.; Johnsen, R.D.; Steinhaus, J.P.; Moulton, H.M.; Iversen, P.L.; Wilton, S.D. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 2007, 15, 1587-1592.
89. Mann, C.J.; Honeyman, K.; Cheng, A.J.; Ly, T.; Lloyd, F.; Fletcher, S.; Morgan, J.E.; Partridge, T.A.; Wilton, S.D. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA 2001, 98, 42-47.
90. McClorey, G.; Fall, A.M.; Moulton, H.M.; Iversen, P.L.; Rasko, J.E.; Ryan, M.; Fletcher, S.; Wilton, S.D. Induced dystrophin exon skipping in human muscle explants. Neuromuscul. Disord. 2006, 16, 583-590.
91. McClorey, G.; Moulton, H.M.; Iversen, P.L.; Fletcher, S.; Wilton, S.D. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 2006, 13, 1373-1381.
92. Mitrpant, C.; Fletcher, S.; Iversen, P.L.; Wilton, S.D. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. J. Gene Med. 2009, 11, 46-56.
93. van Deutekom, J.C.; Bremmer-Bout, M.; Janson, A.A.; Ginjaar, I.B.; Baas, F.; den Dunnen, J.T.; van Ommen, G.J. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 2001, 10, 1547-1554.
94. Wilton, S.D.; Fall, A.M.; Harding, P.L.; McClorey, G.; Coleman, C.; Fletcher, S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol. Ther. 2007, 15, 1288-1296.
95. Takeshima, Y.; Yagi, M.; Wada, H.; Matsuo, M. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle. Brain Dev. 2005, 27, 488-493.
96. Yokota, T.; Hoffman, E.; Takeda, S. Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol. Biol. 2011, 709, 299-312.
97. Cirak, S.; Feng, L.; Anthony, K.; Arechavala-Gomeza, V.; Torelli, S.; Sewry, C.; Morgan, J.E.; Muntoni, F. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol. Ther. 2012, 20, 462-467.
98. Muntoni, F.; Bushby, K.; van Ommen, G. 128th ENMC internationalworkshoponpreclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy 22-24 October 2004, Naarden, The Netherlands. Neuromuscul. Disord. 2005, 15, 450-457.
99. Kinali, M.; Arechavala-Gomeza, V.; Feng, L.; Cirak, S.; Hunt, D.; Adkin, C.; Guglieri, M.; Ashton, E.; Abbs, S.; Nihoyannopoulos, P.; et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009, 8, 918-928.
100. Cirak, S.; Arechavala-Gomeza, V.; Guglieri, M.; Feng, L.; Torelli, S.; Anthony, K.; Abbs, S.; Garralda, M.E.; Bourke, J.; Wells, D.J.; et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 2011, 378, 595-605.
101. Kamoshita, S.; Konishi, Y.; Segawa, M.; Fukuyama, Y. Congenital muscular dystrophy as a disease of the central nervous system. Arch. Neurol. 1976, 33, 513-516.
102. Kobayashi, K.; Nakahori, Y.; Miyake, M.; Matsumura, K.; Kondo-Iida, E.; Nomura, Y.; Segawa, M.; Yoshioka, M.; Saito, K.; Osawa, M.; et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394, 388-392.
103. Michele, D.E.; Barresi, R.; Kanagawa, M.; Saito, F.; Cohn, R.D.; Satz, J.S.; Dollar, J.; Nishino, I.; Kelley, R.I.; Somer, H.; et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002, 418, 417-422.
104. Hayashi, Y.K.; Ogawa, M.; Tagawa, K.; Noguchi, S.; Ishihara, T.; Nonaka, I.; Arahata, K. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001, 57, 115-121.
105. Colombo, R.; Bignamini, A.A.; Carobene, A.; Sasaki, J.; Tachikawa, M.; Kobayashi, K.; Toda, T. Age and origin of the FCMD 3'-untranslated-region retrotransposal insertion mutation causing Fukuyama-type congenital muscular dystrophy in the Japanese population. Hum. genet. 2000, 107, 559-567.
106. Kobayashi, K.; Sasaki, J.; Kondo-Iida, E.; Fukuda, Y.; Kinoshita, M.; Sunada, Y.; Nakamura, Y.; Toda, T. Structural organization, complete genomic sequences and mutational analyses of the Fukuyama-type congenital muscular dystrophy gene, fukutin. FEBS Lett. 2001, 489, 192-196.
107. Cartegni, L.; Wang, J.; Zhu, Z.; Zhang, M.Q.; Krainer, A.R. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003, 31, 3568-3571.
108. Fairbrother, W.G.; Yeo, G.W.; Yeh, R.; Goldstein, P.; Mawson, M.; Sharp, P.A.; Burge, C.B. RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Res. 2004, 32, W187-W190.
109. Fairbrother, W.G.; Yeh, R.F.; Sharp, P.A.; Burge, C.B. Predictive identification of exonic splicing enhancers in human genes. Science 2002, 297, 1007-1013.
110. Bhagavati, S.; Leung, B.; Shafiq, S.A.; Ghatpande, A. Myotonic dystrophy: Decreased levels of myotonin protein kinase (Mt-PK) leads to apoptosis in muscle cells. Exp. Neurol. 1997, 146, 277-281.
111. Meola, G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 2000, 23, 1789-1799.
112. Meola, G. Myotonic dystrophies. Curr. Opin. Neurol. 2000, 13, 519-525.
113. Schoser, B.; Timchenko, L. Myotonic dystrophies 1 and 2: Complex diseases with complex mechanisms. Curr. Genomics 2010, 11, 77-90.
114. Cho, D.H.; Tapscott, S.J. Myotonic dystrophy: Emerging mechanisms for DM1 and DM2. Biochim. Biophys. Acta 2007, 1772, 195-204.
115. Brook, J.D.; McCurrach, M.E.; Harley, H.G.; Buckler, A.J.; Church, D.; Aburatani, H.; Hunter, K.; Stanton, V.P.; Thirion, J.P.; Hudson, T.; et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 68, 799-808.
116. Fu, Y.H.; Pizzuti, A.; Fenwick, R.G., Jr.; King, J.; Rajnarayan, S.; Dunne, P.W.; Dubel, J.; Nasser, G.A.; Ashizawa, T.; de Jong, P.; et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992, 255, 1256-1258.
117. Liquori, C.L.; Ricker, K.; Moseley, M.L.; Jacobsen, J.F.; Kress, W.; Naylor, S.L.; Day, J.W.; Ranum, L.P. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293, 864-867.
118. Mahadevan, M.; Tsilfidis, C.; Sabourin, L.; Shutler, G.; Amemiya, C.; Jansen, G.; Neville, C.; Narang, M.; Barcelo, J.; O'Hoy, K.; et al. Myotonic dystrophy mutation: An unstable CTG repeat in the 3' untranslated region of the gene. Science 1992, 255, 1253-1255.
119. Hamshere, M.G.; Harley, H.; Harper, P.; Brook, J.D.; Brookfield, J.F. Myotonic dystrophy: The correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. J. Med. Genet. 1999, 36, 59-61.
120. Harper, P. Myotonic Dystrophy, 3rd ed.; W B Saunders: London, UK, 2001.
121. Taneja, K.L.; McCurrach, M.; Schalling, M.; Housman, D.; Singer, R.H. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 1995, 128, 995-1002.
122. Wang, J.; Pegoraro, E.; Menegazzo, E.; Gennarelli, M.; Hoop, R.C.; Angelini, C.; Hoffman, E.P. Myotonic dystrophy: Evidence for a possible dominant-negative RNA mutation. Hum. Mol. Genet. 1995, 4, 599-606.
123. Magana, J.J.; Cisneros, B. Perspectives on gene therapy in myotonic dystrophy type 1. J. Neurosci. Res. 2011, 89, 275-285.
124. Foff, E.P.; Mahadevan, M.S. Therapeutics development in myotonic dystrophy type 1. Muscle Nerve 2011, 44, 160-169.
125. Carango, P.; Noble, J.E.; Marks, H.G.; Funanage, V.L. Absence of myotonic dystrophy protein kinase (DMPK) mRNA as a result of a triplet repeat expansion in myotonic dystrophy. Genomics 1993, 18, 340-348.
126. Hofmann-Radvanyi, H.; Lavedan, C.; Rabes, J.P.; Savoy, D.; Duros, C.; Johnson, K.; Junien, C. Myotonic dystrophy: Absence of CTG enlarged transcript in congenital forms, and low expression of the normal allele. Hum. Mol. Genet. 1993, 2, 1263-1266.
127. Koga, R.; Nakao, Y.; Kurano, Y.; Tsukahara, T.; Nakamura, A.; Ishiura, S.; Nonaka, I.; Arahata, K. Decreased myotonin-protein kinase in the skeletal and cardiac muscles in myotonic dystrophy. Biochem. Biophys. Res. Commun. 1994, 202, 577-585.
128. Krahe, R.; Ashizawa, T.; Abbruzzese, C.; Roeder, E.; Carango, P.; Giacanelli, M.; Funanage, V.L.; Siciliano, M.J. Effect of myotonic dystrophy trinucleotide repeat expansion on DMPK transcription and processing. Genomics 1995, 28, 1-14.
129. Maeda, M.; Taft, C.S.; Bush, E.W.; Holder, E.; Bailey, W.M.; Neville, H.; Perryman, M.B.; Bies, R.D. Identification, tissue-specific expression, and subcellular localization of the 80- and 71-kDa forms of myotonic dystrophy kinase protein. J. Biol. Chem. 1995, 270, 20246-20249.
130. Novelli, G.; Gennarelli, M.; Zelano, G.; Pizzuti, A.; Fattorini, C.; Caskey, C.T.; Dallapiccola, B. Failure in detecting mRNA transcripts from the mutated allele in myotonic dystrophy muscle. Biochem. Mol. Biol. Int. 1993, 29, 291-297.
131. Reddy, S.; Smith, D.B.; Rich, M.M.; Leferovich, J.M.; Reilly, P.; Davis, B.M.; Tran, K.; Rayburn, H.; Bronson, R.; Cros, D.; et al. Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat. Genet. 1996, 13, 325-335.
132. Gonzalez-Barriga, A.; Mulders, S.A.; van de Giessen, J.; Hooijer, J.D.; Bijl, S.; van Kessel, I.D.; van Beers, J.; van Deutekom, J.C.; Fransen, J.A.; Wieringa, B.;. et al. Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol. Ther. Nucleic Acids 2013, 2, e81.
133. Lee, J.E.; Bennett, C.F.; Cooper, T.A. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc. Natl. Acad. Sci. USA 2012, 109, 4221-4226.
134. Leger, A.J.; Mosquea, L.M.; Clayton, N.P.; Wu, I.H.; Weeden, T.; Nelson, C.A.; Phillips, L.; Roberts, E.; Piepenhagen, P.A.; Cheng, S.H.; et al. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid Ther. 2013, 23, 109-117.
135. Wirth, B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat. 2000, 15, 228-237.
136. Wirth, B.; Herz, M.; Wetter, A.; Moskau, S.; Hahnen, E.; Rudnik-Schoneborn, S.; Wienker, T.; Zerres, K. Quantitative analysis of survival motor neuron copies: Identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am. J. Hum. Genet. 1999, 64, 1340-1356.
137. Zellweger, H. The genetic heterogeneity of spinal muscular atrophy (SMA). Birth Defects Orig. Artic. Ser. 1971, 7, 82-89.
138. Monani, U.R.; Lorson, C.L.; Parsons, D.W.; Prior, T.W.; Androphy, E.J.; Burghes, A.H.; McPherson, J.D. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8, 1177-1183.
139. Khoo, B.; Krainer, A.R. Splicing therapeutics in SMN2 and APOB. Curr. Opin. Mol. Ther. 2009, 11, 108-115.
140. Markowitz, J.A.; Singh, P.; Darras, B.T. Spinal muscular atrophy: A clinical and research update. Pediatr. Neurol. 2012, 46, 1-12.
141. Kolb, S.J.; Kissel, J.T. Spinal muscular atrophy: A timely review. Arch. Neurol. 2011, 68, 979-984.
142. Lorson, C.L.; Rindt, H.; Shababi, M. Spinal muscular atrophy: Mechanisms and therapeutic strategies. Hum. Mol. Genet. 2010, 19, R111-R118.
143. van Meerbeke, J.P.; Sumner, C.J. Progress and promise: The current status of spinal muscular atrophy therapeutics. Discov. Med. 2011, 12, 291-305.
144. Mitrpant, C.; Porensky, P.; Zhou, H.; Price, L.; Muntoni, F.; Fletcher, S.; Wilton, S.D.; Burghes, A.H. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: Towards a treatment for spinal muscular atrophy. PLoS One 2013, 8, e62114.
145. Liu, J.; Aoki, M.; Illa, I.; Wu, C.; Fardeau, M.; Angelini, C.; Serrano, C.; Urtizberea, J.A.; Hentati, F.; Hamida, M.B.; et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 1998, 20, 31-36.
146. Aoki, M.; Liu, J.; Richard, I.; Bashir, R.; Britton, S.; Keers, S.M.; Oeltjen, J.; Brown, H.E.; Marchand, S.; Bourg, N.; et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001, 57, 271-278.
147. Anderson, L.V.; Davison, K.; Moss, J.A.; Young, C.; Cullen, M.J.; Walsh, J.; Johnson, M.A.; Bashir, R.; Britton, S.; Keers, S.; et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum. Mol. Genet. 1999, 8, 855-861.
148. Argov, Z.; Sadeh, M.; Mazor, K.; Soffer, D.; Kahana, E.; Eisenberg, I.; Mitrani-Rosenbaum, S.; Richard, I.; Beckmann, J.; Keers, S.; et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 2000, 123, 1229-1237.
149. Foxton, R.M.; Laval, S.H.; Bushby, K.M. Characterisation of the dysferlin skeletal muscle promoter. Eur. J. Hum. Genet. 2004, 12, 127-131.
150. Guglieri, M.; Bushby, K. How to go about diagnosing and managing the limb-girdle muscular dystrophies. Neurol. India 2008, 56, 271-280.
151. Guglieri, M.; Straub, V.; Bushby, K.; Lochmuller, H. Limb-girdle muscular dystrophies. Curr. Opin. Neurol. 2008, 21, 576-584.
152. Illa, I.; Serrano-Munuera, C.; Gallardo, E.; Lasa, A.; Rojas-Garcia, R.; Palmer, J.; Gallano, P.; Baiget, M.; Matsuda, C.; Brown, R.H. Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol. 2001, 49, 130-134.
153. Bansal, D.; Miyake, K.; Vogel, S.S.; Groh, S.; Chen, C.C.; Williamson, R.; McNeil, P.L.; Campbell, K.P. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423, 168-172.
154. Bansal, D.; Campbell, K.P. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol. 2004, 14, 206-213.
155. Cai, C.; Weisleder, N.; Ko, J.K.; Komazaki, S.; Sunada, Y.; Nishi, M.; Takeshima, H.; Ma, J. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J. Biol. Chem. 2009, 284, 15894-15902.
156. Han, R.; Bansal, D.; Miyake, K.; Muniz, V.P.; Weiss, R.M.; McNeil, P.L.; Campbell, K.P. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J. Clin. Invest. 2007, 117, 1805-1813.
157. Han, R.; Campbell, K.P. Dysferlin and muscle membrane repair. Curr. Opin. Cell Biol. 2007, 19, 409-416.
158. Lennon, N.J.; Kho, A.; Bacskai, B.J.; Perlmutter, S.L.; Hyman, B.T.; Brown, R.H., Jr. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J. Biol. Chem. 2003, 278, 50466-50473.
159. Matsuda, C.; Aoki, M.; Hayashi, Y.K.; Ho, M.F.; Arahata, K.; Brown, R.H., Jr. Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology 1999, 53, 1119-1122.
160. Aartsma-Rus, A.; Singh, K.H.; Fokkema, I.F.; Ginjaar, I.B.; van Ommen, G.J.; den Dunnen, J.T.; van der Maarel, S.M. Therapeutic exon skipping for dysferlinopathies? Eur. J. Hum. Genet. 2010, 18, 889-894.
161. Wein, N.; Avril, A.; Bartoli, M.; Beley, C.; Chaouch, S.; Laforet, P.; Behin, A.; Butler-Browne, G.; Mouly, V.; Krahn, M.; et al. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum. Mutat. 2010, 31, 136-142.
162. Sinnreich, M.; Therrien, C.; Karpati, G. Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 2006, 66, 1114-1116.
163. Rothstein, J.D. ALS-Motor neuron disease: Mechanism and development of new therapies. J. Vis. Exp. 2007, e245.
164. Turner, M.; Al-Chalabi, A. Early symptom progression rate is related to ALS outcome: A prospective population-based study. Neurology 2002, 59, 2012-2013.
165. Cleveland, D.W. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS. Neuron 1999, 24, 515-520.
166. Cheah, B.C.; Vucic, S.; Krishnan, A.V.; Boland, R.A.; Kiernan, M.C. Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotroph. Lateral Scler. 2011, 12, 33-38.
167. Morariu, M.A. A new classification of amyotrophic lateral sclerosis (ALS) and familial amyotrophic lateral sclerosis (FALS). Dis. Nerv. Syst. 1977, 38, 468-469.
168. Armani, M.; Pierobon-Bormioli, S.; Mostacciuolo, M.L.; Cacciavillani, M.; Cassol, M.A.; Candeago, R.M.; Angelini, C. Familial ALS: Clinical, genetic and morphological features. Adv. Exp. Med. Biol. 1987, 209, 109-110.
169. Penco, S.; Schenone, A.; Bordo, D.; Bolognesi, M.; Abbruzzese, M.; Bugiani, O.; Ajmar, F.; Garre, C. A SOD1 gene mutation in a patient with slowly progressing familial ALS. Neurology 1999, 53, 404-406.
170. Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.; Sisodia, S.S.; Cleveland, D.W.; Price, D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14, 1105-1116.
171. Bruijn, L.I.; Miller, T.M.; Cleveland, D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27, 723-749.
172. Deng, H.X.; Hentati, A.; Tainer, J.A.; Iqbal, Z.; Cayabyab, A.; Hung, W.Y.; Getzoff, E.D.; Hu, P.; Herzfeldt, B.; Roos, R.P.; et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993, 261, 1047-1051.
173. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59-62.
174. Bruijn, L.I.; Houseweart, M.K.; Kato, S.; Anderson, K.L.; Anderson, S.D.; Ohama, E.; Reaume, A.G.; Scott, R.W.; Cleveland, D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281, 1851-1854.
175. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X.; et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264, 1772-1775.
176. Ratovitski, T.; Corson, L.B.; Strain, J.; Wong, P.; Cleveland, D.W.; Culotta, V.C.; Borchelt, D.R. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum. Mol. Genet. 1999, 8, 1451-1460.
177. Saccon, R.A.; Bunton-Stasyshyn, R.K.; Fisher, E.M.; Fratta, P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 2013, doi:10.1093/brain/awt097
178. Winklhofer, K.F.; Tatzelt, J.; Haass, C. The two faces of protein misfolding: Gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008, 27, 336-349.
179. Zuccato, C.; Valenza, M.; Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90, 905-981.
180. Devos, S.L.; Miller, T.M. Antisense oligonucleotides: Treating neurodegeneration at the level of RNA. Neurotherapeutics 2013, 10, 486-497.
181. Deng, H.X.; Chen, W.; Hong, S.T.; Boycott, K.M.; Gorrie, G.H.; Siddique, N.; Yang, Y.; Fecto, F.; Shi, Y.; Zhai, H.; et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477, 211-215.
182. Johnson, J.O.; Mandrioli, J.; Benatar, M.; Abramzon, Y.; van Deerlin, V.M.; Trojanowski, J.Q.; Gibbs, J.R.; Brunetti, M.; Gronka, S.; Wuu, J.; et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68, 857-864.
183. Koppers, M.; van Blitterswijk, M.M.; Vlam, L.; Rowicka, P.A.; van Vught, P.W.; Groen, E.J.; Spliet, W.G.; Engelen-Lee, J.; Schelhaas, H.J.; de Visser, M.; et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33, 837.e7-837.e13.
184. Kwiatkowski, T.J., Jr.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vanderburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E.J.; Munsat, T.; et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323, 1205-1208.
185. Mosca, L.; Lunetta, C.; Tarlarini, C.; Avemaria, F.; Maestri, E.; Melazzini, M.; Corbo, M.; Penco, S. Wide phenotypic spectrum of the TARDBP gene: Homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiol. Aging 2012, 33, 1846.e1-1846.e4.
186. Neumann, M.; Sampathu, D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C.M.; et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314, 130-133.
187. van Es, M.A.; Diekstra, F.P.; Veldink, J.H.; Baas, F.; Bourque, P.R.; Schelhaas, H.J.; Strengman, E.; Hennekam, E.A.; Lindhout, D.; Ophoff, R.A.; et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology 2009, 72, 287-288.
188. van Langenhove, T.; van der Zee, J.; Sleegers, K.; Engelborghs, S.; Vandenberghe, R.; Gijselinck, I.; van den Broeck, M.; Mattheijssens, M.; Peeters, K.; ve Deyn, P.P.; et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 2010, 74, 366-371.
189. Vance, C.; Rogelj, B.; Hortobagyi, T.; de Vos, K.J.; Nishimura, A.L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323, 1208-1211.
190. Byrne, S.; Elamin, M.; Bede, P.; Shatunov, A.; Walsh, C.; Corr, B.; Heverin, M.; Jordan, N.; Kenna, K.; Lynch, C.; et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study. Lancet Neurol. 2012, 11, 232-240.
191. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72, 245-256.
192. Harms, M.B.; Cady, J.; Zaidman, C.; Cooper, P.; Bali, T.; Allred, P.; Cruchaga, C.; Baughn, M.; Libby, R.T.; Pestronk, A.; et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiol. Aging 2013, 34, 2234.e13-2234.e19.
193. Majounie, E.; Renton, A.E.; Mok, K.; Dopper, E.G.; Waite, A.; Rollinson, S.; Chio, A.; Restagno, G.; Nicolaou, N.; Simon-Sanchez, J.; et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012, 11, 323-330.
194. Mok, K.Y.; Koutsis, G.; Schottlaender, L.V.; Polke, J.; Panas, M.; Houlden, H. High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients. Neurobiol. Aging 2012, 33, 1851.e1-1851.e5.
195. Renton, A.E.; Majounie, E.; Waite, A.; Simon-Sanchez, J.; Rollinson, S.; Gibbs, J.R.; Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72, 257-268.
196. Smith, B.N.; Newhouse, S.; Shatunov, A.; Vance, C.; Topp, S.; Johnson, L.; Miller, J.; Lee, Y.; Troakes, C.; Scott, K.M.; et al. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur. J. Hum. Genet. 2013, 21, 102-108.
197. van Blitterswijk, M.; DeJesus-Hernandez, M.; Rademakers, R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: Can we learn from other noncoding repeat expansion disorders? Curr. Opin. Neurol. 2012, 25, 689-700.
198. Garcia-Redondo, A.; Dols-Icardo, O.; Rojas-Garcia, R.; Esteban-Perez, J.; Cordero-Vazquez, P.; Munoz-Blanco, J.L.; Catalina, I.; Gonzalez-Munoz, M.; Varona, L.; Sarasola, E.; et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum. Mutat. 2013, 34, 79-82.
199. Rutherford, N.J.; DeJesus-Hernandez, M.; Baker, M.C.; Kryston, T.B.; Brown, P.E.; Lomen-Hoerth, C.; Boylan, K.; Wszolek, Z.K.; Rademakers, R. C9ORF72 hexanucleotide repeat expansions in patients with ALS from the Coriell Cell Repository. Neurology 2012, 79, 482-483.
200. Rutherford, N.J.; Heckman, M.G.; Dejesus-Hernandez, M.; Baker, M.C.; Soto-Ortolaza, A.I.; Rayaprolu, S.; Stewart, H.; Finger, E.; Volkening, K.; Seeley, W.W.; et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol. Aging 2012, 33, 2950.e5-2950.e7.
201. Cruts, M.; Gijselinck, I.; van Langenhove, T.; van der Zee, J.; van Broeckhoven, C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013, in press.
202. Nuytemans, K.; Bademci, G.; Kohli, M.M.; Beecham, G.W.; Wang, L.; Young, J.I.; Nahab, F.; Martin, E.R.; Gilbert, J.R.; Benatar, M.; et al. C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. Ann. Hum. Genet. 2013, doi:10.1111/ahg.12033
203. Rademakers, R. C9orf72 repeat expansions in patients with ALS and FTD. Lancet Neurol. 2012, 11, 297-298.
204. Dance, A. Alzheimer Research Forum. In Proceedings of 23rd Annual International Symposium on ALS/MND, Chicago, IL, USA, 5-7 December 2012.
205. Donnelly, C.J.; Ostrow, L.W.; Zhang, P.; Vidensky, S.; Hoover, B.N.; Balasubramanian, U.; Li, Y.; Maragakis, N.J.; Tienari, P.; Traynor, B.J.; et al. Development of a C9ORF72 ALS Antisense Therapy and a Therapeutic Biomarker. Presented at the 2012 Neuroscience Meeting Planner, New Orleans, LA, USA, 17 October 2012.
206. Craufurd, D.; Thompson, J.C.; Snowden, J.S. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 2001, 14, 219-226.
207. Frank, S.; Ondo, W.; Fahn, S.; Hunter, C.; Oakes, D.; Plumb, S.; Marshall, F.; Shoulson, I.; Eberly, S.; Walker, F.; et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin. Neuropharmacol. 2008, 31, 127-133.
208. Arnulf, I.; Nielsen, J.; Lohmann, E.; Schiefer, J.; Wild, E.; Jennum, P.; Konofal, E.; Walker, M.; Oudiette, D.; Tabrizi, S.; et al. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 2008, 65, 482-488.
209. Carlock, L.; Walker, P.D.; Shan, Y.; Gutridge, K. Transcription of the Huntington disease gene during the quinolinic acid excitotoxic cascade. Neuroreport 1995, 6, 1121-1124.
210. Burns, A.; Folstein, S.; Brandt, J.; Folstein, M. Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J. Nerv. Ment. Dis. 1990, 178, 20-26.
211. Marder, K.; Zhao, H.; Myers, R.H.; Cudkowicz, M.; Kayson, E.; Kieburtz, K.; Orme, C.; Paulsen, J.; Penney, J.B., Jr.; Siemers, E.; et al. Rate of functional decline in Huntington's disease. Neurology 2000, 54, 452-458.
212. Reiner, A.; Albin, R.L.; Anderson, K.D.; D'Amato, C.J.; Penney, J.B.; Young, A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 1988, 85, 5733-5737.
213. Rosas, H.D.; Hevelone, N.D.; Zaleta, A.K.; Greve, D.N.; Salat, D.H.; Fischl, B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65, 745-747.
214. Cha, J.H.; Kosinski, C.M.; Kerner, J.A.; Alsdorf, S.A.; Mangiarini, L.; Davies, S.W.; Penney, J.B.; Bates, G.P.; Young, A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA 1998, 95, 6480-6485.
215. Ross, C.A.; Shoulson, I. Huntington disease: Pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat. Disord. 2009, 15, S135-S138.
216. Liu, J.P.; Zeitlin, S.O. The long and the short of aberrant ciliogenesis in Huntington disease. J. Clin. Invest. 2011, 121, 4237-4241.
217. Urbaniak Hunter, K.; Yarbrough, C.; Ciacci, J. Gene- and cell-based approaches for neurodegenerative disease. Adv. Exp. Med. Biol. 2010, 671, 117-130.
218. Rubinsztein, D.C.; Barton, D.E.; Davison, B.C.; Ferguson-Smith, M.A. Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum. Mol. Genet. 1993, 2, 1713-1715.
219. Aronin, N.; Chase, K.; Young, C.; Sapp, E.; Schwarz, C.; Matta, N.; Kornreich, R.; Landwehrmeyer, B.; Bird, E.; Beal, M.F.; et al. CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. Neuron 1995, 15, 1193-1201.
220. Becher, M.W.; Kotzuk, J.A.; Sharp, A.H.; Davies, S.W.; Bates, G.P.; Price, D.L.; Ross, C.A. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 1998, 4, 387-397.
221. Gutekunst, C.A.; Li, S.H.; Yi, H.; Mulroy, J.S.; Kuemmerle, S.; Jones, R.; Rye, D.; Ferrante, R.J.; Hersch, S.M.; Li, X.J. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J. Neurosci. 1999, 19, 2522-2534.
222. Myers, R.H.; Vonsattel, J.P.; Stevens, T.J.; Cupples, L.A.; Richardson, E.P.; Martin, J.B.; Bird, E.D. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 1988, 38, 341-347.
223. DiFiglia, M.; Sapp, E.; Chase, K.; Schwarz, C.; Meloni, A.; Young, C.; Martin, E.; Vonsattel, J.P.; Carraway, R.; Reeves, S.A.; et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14, 1075-1081.
224. Ferrante, R.J.; Gutekunst, C.A.; Persichetti, F.; McNeil, S.M.; Kowall, N.W.; Gusella, J.F.; MacDonald, M.E.; Beal, M.F.; Hersch, S.M. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 1997, 17, 3052-3063.
225. Hoogeveen, A.T.; Willemsen, R.; Meyer, N.; de Rooij, K.E.; Roos, R.A.; van Ommen, G.J.; Galjaard, H. Characterization and localization of the Huntington disease gene product. Hum. Mol. Genet. 1993, 2, 2069-2073.
226. Nasir, J.; Floresco, S.B.; O'Kusky, J.R.; Diewert, V.M.; Richman, J.M.; Zeisler, J.; Borowski, A.; Marth, J.D.; Phillips, A.G.; Hayden, M.R. Targeted disruption of the Huntington's diseasegene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81, 811-823.
227. White, J.K.; Auerbach, W.; Duyao, M.P.; Vonsattel, J.P.; Gusella, J.F.; Joyner, A.L.; MacDonald, M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 1997, 17, 404-410.
228. Rigamonti, D.; Bauer, J.H.; De-Fraja, C.; Conti, L.; Sipione, S.; Sciorati, C.; Clementi, E.; Hackam, A.; Hayden, M.R.; Li, Y.; et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 2000, 20, 3705-3713.
229. Zhang, Y.; Leavitt, B.R.; van Raamsdonk, J.M.; Dragatsis, I.; Goldowitz, D.; MacDonald, M.E.; Hayden, M.R.; Friedlander, R.M. Huntingtin inhibits caspase-3 activation. EMBO J. 2006, 25, 5896-5906.
230. Gauthier, L.R.; Charrin, B.C.; Borrell-Pages, M.; Dompierre, J.P.; Rangone, H.; Cordelieres, F.P.; de Mey, J.; MacDonald, M.E.; Lessmann, V.; Humbert, S.; et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118, 127-138.
231. Velier, J.; Kim, M.; Schwarz, C.; Kim, T.W.; Sapp, E.; Chase, K.; Aronin, N.; DiFiglia, M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol.1998, 152, 34-40.
232. Gunawardena, S.; Her, L.S.; Brusch, R.G.; Laymon, R.A.; Niesman, I.R.; Gordesky-Gold, B.; Sintasath, L.; Bonini, N.M.; Goldstein, L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40, 25-40.
233. Trushina, E.; Dyer, R.B.; Badger, J.D., 2nd.; Ure, D.; Eide, L.; Tran, D.D.; Vrieze, B.T.; Legendre-Guillemin, V.; McPherson, P.S.; Mandavilli, B.S.; et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 2004, 24, 8195-8209.
234. Smith, R.; Brundin, P.; Li, J.Y. Synaptic dysfunction in Huntington's disease: A new perspective. Cell. Mol. Life Sci. 2005, 62, 1901-1912.
235. Parker, J.A.; Metzler, M.; Georgiou, J.; Mage, M.; Roder, J.C.; Rose, A.M.; Hayden, M.R.; Neri, C. Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. J. Neurosci. 2007, 27, 11056-11064.
236. Dragatsis, I.; Levine, M.S.; Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 2000, 26, 300-306.
237. Boudreau, R.L.; McBride, J.L.; Martins, I.; Shen, S.; Xing, Y.; Carter, B.J.; Davidson, B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacyinHuntington'sdiseasemice.Mol. Ther. 2009, 17, 1053-1063.
238. Drouet, V.; Perrin, V.; Hassig, R.; Dufour, N.; Auregan, G.; Alves, S.; Bonvento, G.; Brouillet, E.; Luthi-Carter, R.; Hantraye, P.; et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009, 65, 276-285.
239. Kordasiewicz, H.B.; Stanek, L.M.; Wancewicz, E.V.; Mazur, C.; McAlonis, M.M.; Pytel, K.A.; Artates, J.W.; Weiss, A.; Cheng, S.H.; Shihabuddin, L.S.; et al. Sustained therapeutic reversal of Huntington's disease by transient repression of hunting tin synthesis. Neuron 2012, 74, 1031-1044.
240. Lombardi, M.S.; Jaspers, L.; Spronkmans, C.; Gellera, C.; Taroni, F.; di Maria, E.; Donato, S.D.; Kaemmerer,W.F. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 2009, 217, 312-319.
241. Pfister, E.L.; Kennington, L.; Straubhaar, J.; Wagh, S.; Liu, W.; DiFiglia, M.; Landwehrmeyer, B.; Vonsattel, J.P.; Zamore, P.D.; Aronin, N. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 2009, 19, 774-778.
242. van Bilsen, P.H.; Jaspers, L.; Lombardi, M.S.; Odekerken, J.C.; Burright, E.N.; Kaemmerer, W.F. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther. 2008, 19, 710-719.
243. Hu, J.; Matsui, M.; Corey, D.R. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann. N. Y. Acad. Sci. 2009, 1175, 24-31.
244. Hu, J.; Matsui, M.; Gagnon, K.T.; Schwartz, J.C.; Gabillet, S.; Arar, K.; Wu, J.; Bezprozvanny, I.; Corey, D.R. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 2009, 27, 478-484.
245. Gagnon, K.T.; Pendergraff, H.M.; Deleavey, G.F.; Swayze, E.E.; Potier, P.; Randolph, J.; Roesch, E.B.; Chattopadhyaya, J.; Damha, M.J.; Bennett, C.F.; et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 2010, 49, 10166-10178.
246. DiFiglia, M.; Sena-Esteves, M.; Chase, K.; Sapp, E.; Pfister, E.; Sass, M.; Yoder, J.; Reeves, P.; Pandey, R.K.; Rajeev, K.G.; et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. USA 2007, 104, 17204-17209.
247. Harper, S.Q.; Staber, P.D.; He, X.; Eliason, S.L.; Martins, I.H.; Mao, Q.; Yang, L.; Kotin, R.M.; Paulson, H.L.; Davidson, B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 2005, 102, 5820-5825.
248. Yamamoto, A.; Lucas, J.J.; Hen, R. Reversal of neuropathology and motor dysfunction in a conditiona lmodel of Huntington's disease. Cell 2000, 101, 57-66.
249. Boado, R.J.; Kazantsev, A.; Apostol, B.L.; Thompson, L.M.; Pardridge, W.M. Antisense-mediated down-regulation of the human huntingtin gene. J. Pharmacol. Exp. Ther. 2000, 295, 239-243.
250. Hu, J.; Dodd, D.W.; Hudson, R.H.; Corey, D.R. Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine. Bioorg. Med. Chem. Lett. 2009, 19, 6181-6184.
251. Nellemann, C.; Abell, K.; Norremolle, A.; Lokkegaard, T.; Naver, B.; Ropke, C.; Rygaard, J.; Sorensen, S.A.; Hasholt, L. Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol. Cell. Neurosci. 2000, 16, 313-323.
252. Fiszer, A.; Olejniczak, M.; Switonski, P.M.; Wroblewska, J.P.; Wisniewska-Kruk, J.; Mykowska, A.; Krzyzosiak, W.J. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. BMC Mol. Biol. 2012, 13, e6.
253. Douglas, A.G.; Wood, M.J. Splicing therapy for neuromuscular disease. Mol. Cell. Neurosci. 2013, 56, 169-185.